Gujarat Themis Biosyn Quarterly Results for Trading Insights
In Mar 2026, Gujarat Themis Biosyn (GUJTHEM) reported revenue ₹45 Cr and net profit ₹11 Cr. For annual financials, live price and key ratios, visit Gujarat Themis Biosyn share price chart.
GUJTHEM Quarterly Results — Revenue, Profit & EPS Highlights
Gujarat Themis Biosyn latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View GUJTHEM 52-week performance for the annual high/low range and current price position.
- Revenue of ₹45 Cr in Mar 2026 (+2.3% vs Jun 2026)
- Net Profit of ₹11 Cr in Mar 2026 (+0.0% vs Jun 2026)
- EBITDA of ₹20 Cr in Mar 2026 (-4.8% vs Jun 2026)
- Operating Margin of 44.0% in Mar 2026 (-3.0pp vs Jun 2026)
- Earnings Per Share of ₹1.00 in Mar 2026 (-2.0% vs Jun 2026)
Gujarat Themis Biosyn Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GUJTHEM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 45 | 44 | 36 | 2.3% | - |
| Net Profit (₹ Cr) | 11 | 11 | 9 | - | - |
| EBITDA (₹ Cr) | 20 | 21 | 14 | - | - |
| EPS (₹) | 1.00 | 1.02 | 0.83 | - | - |
| Operating Margin (%) | 44.0% | 47.0% | 39.0% | - | - |
GUJTHEM Share Price Trend — 1-Year Movement Across Quarterly Results
Gujarat Themis Biosyn 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse GUJTHEM institutional holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GUJTHEM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gujarat Themis Biosyn latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores